Balancing Multivalent Avidity and Receptor Availability Governs mRNA Delivery by Antibody-Functionalized Lipid Nanoparticles
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Expanding the therapeutic scope of mRNA requires delivery systems with precise cell selectivity. Antibody-functionalized lipid nanoparticles (LNPs) enable programmable targeting, but quantitative rules linking surface avidity to delivery remain unresolved. Here, we establish a single-domain antibody (VHH)-LNP platform with controlled orientation and tunable ligand density, combined with an antigen-specific ligand binding fluorescence assay using single-particle nanoflow cytometry to quantify only functional ligands. Using this system, we show that CD8-targeted LNPs exhibit a bell-shaped dependence of delivery efficiency on ligand density, revealing an optimal avidity of ∼0.1 VHH per 100 nm 2 . Mechanistically, excessive ligand density induces receptor degradation, while optimal avidity balances multivalent engagement with receptor preservation. Optimized LNPs achieve selective mRNA expression in CD8 + T cells and enable in vivo CAR-T generation, resulting in dose-dependent B cell depletion at 10–30 μg/kg. Surface avidity thus emerges as a quantitative design parameter, transforming antibody-decorated LNP engineering from empirical to rule-based design.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · CAR-T cell therapy research · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2 Shimohozumi, Ibaraki, Osaka 567-8680, Japan
Funding
Nitto Denko Corporation
References (46)
Show source-provided references
1. 10.1038/s41392-024-02002-z10.1038/s41392-024-02002-z ↗
2. 10.1016/S0140-6736(23)02444-310.1016/S0140-6736(23)02444-3 ↗
3. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
4. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
5. 10.1016/j.tips.2024.03.00410.1016/j.tips.2024.03.004 ↗
6. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
7. 10.1126/sciadv.abf439810.1126/sciadv.abf4398 ↗
8. 10.1002/adma.20190225110.1002/adma.201902251 ↗
9. 10.1021/acs.nanolett.4c0256610.1021/acs.nanolett.4c02566 ↗
10. 10.1126/science.ads847310.1126/science.ads8473 ↗
11. 10.1038/nbt139610.1038/nbt1396 ↗
12. 10.1038/s41467-023-37465-110.1038/s41467-023-37465-1 ↗
13. 10.1002/hep.3218110.1002/hep.32181 ↗
14. 10.1056/NEJMc250952210.1056/NEJMc2509522 ↗
15. 10.1021/acsnano.2c0208410.1021/acsnano.2c02084 ↗
16. 10.1016/j.nano.2012.05.01510.1016/j.nano.2012.05.015 ↗
17. 10.1039/D5NA00323G10.1039/D5NA00323G ↗
18. 10.1016/j.jconrel.2024.05.03610.1016/j.jconrel.2024.05.036 ↗
19. 10.1021/acsnano.4c1656210.1021/acsnano.4c16562 ↗
20. 10.1002/smll.20240963510.1002/smll.202409635 ↗
21. 10.1016/j.mtadv.2022.10029910.1016/j.mtadv.2022.100299 ↗
22. 10.1016/j.ijpharm.2021.12096610.1016/j.ijpharm.2021.120966 ↗
23. 10.1038/s41565-025-01954-910.1038/s41565-025-01954-9 ↗
24. 10.1021/acsnano.1c0827710.1021/acsnano.1c08277 ↗
25. 10.1080/17425247.2023.228637110.1080/17425247.2023.2286371 ↗
26. 10.3389/fddev.2024.136030210.3389/fddev.2024.1360302 ↗
27. 10.1084/jem.2013166010.1084/jem.20131660 ↗
28. 10.1126/sciadv.abc439710.1126/sciadv.abc4397 ↗
29. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
30. 10.1038/s41467-021-27493-010.1038/s41467-021-27493-0 ↗
31. 10.1002/smsc.20220007110.1002/smsc.202200071 ↗
32. 10.1038/s12276-022-00860-710.1038/s12276-022-00860-7 ↗
33. 10.1111/cei.1365910.1111/cei.13659 ↗
34. 10.1111/j.1365-2249.2009.03933.x10.1111/j.1365-2249.2009.03933.x ↗
35. 10.1182/blood-2002-10-324110.1182/blood-2002-10-3241 ↗
36. 10.1021/nn505162u10.1021/nn505162u ↗
37. 10.1016/j.fmre.2022.09.01110.1016/j.fmre.2022.09.011 ↗
38. 10.1016/j.biomaterials.2021.12133910.1016/j.biomaterials.2021.121339 ↗
39. 10.1089/hum.2024.10610.1089/hum.2024.106 ↗
40. 10.1016/j.ijpharm.2020.11979210.1016/j.ijpharm.2020.119792 ↗
41. 10.1056/NEJMoa171615310.1056/NEJMoa1716153 ↗
42. 10.1089/nat.2018.073410.1089/nat.2018.0734 ↗
43. 10.1002/ame2.1235310.1002/ame2.12353 ↗
44. 10.3389/frhem.2022.106270510.3389/frhem.2022.1062705 ↗
45. 10.1002/advs.20230137710.1002/advs.202301377 ↗
46. 10.1016/j.ymthe.2022.02.00110.1016/j.ymthe.2022.02.001 ↗